Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;20(3):843-54.
doi: 10.3233/JAD-2010-091504.

Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging

Lisa Mosconi  1 , Valentina Berti, Lidia Glodzik, Alberto Pupi, Susan De Santi, Mony J de Leon
Affiliations
Review

Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging

Lisa Mosconi et al. J Alzheimers Dis. 2010.

Abstract

The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit from biomarkers that are sensitive to subtle brain changes occurring in the preclinical stage of the disease. Early diagnostics is necessary to identify and treat at risk individuals before irreversible neuronal loss occurs. In vivo imaging has long been used to evaluate brain structural and functional abnormalities as predictors of future AD in non-demented persons. Prior to development of amyloid-beta (Abeta) tracers for positron emission tomography (PET), the most widely utilized PET tracer in AD was 2-[18F]fluoro-2-Deoxy-D-glucose (FDG) PET. For over 20 years, FDG-PET has been used to measure cerebral metabolic rates of glucose (CMRglc), a proxy for neuronal activity, in AD. Many studies have shown that CMRglc reductions occur early in AD, correlate with disease progression, and predict histopathological diagnosis. This paper reviews reports of clinical and preclinical CMRglc reductions observed in association with genetic and non-genetic risk factors for AD. We then briefly review brain Abeta PET imaging studies in AD and discuss the potential of combining symptoms-sensitive FDG-PET measures with pathology-specific Abeta-PET to improve the early detection of AD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Brain regions showing reduced CMRglc on FDG-PET in cognitively normal individuals with a maternal family history of AD (FHm) as compared to demographically matched subjects with a paternal family history (FHp) and with a negative family history of AD (FH-) [57]. Statistical parametric maps showing regions of hypometabolism in NL FHm are displayed on a purple-to-yellow color coded scale at P<0.001. Figure shows the left lateral and superior views of a 3D volume-rendered MRI.
Figure 2
Figure 2
Coregistered PIB and FDG-PET scans in 2 representative cognitively normal individuals at conceivably low risk for AD (top row: negative PIB and normal FDG uptake), and at high risk for AD (bottom row: positive PIB and reduced FDG uptake) based on PET imaging findings. Cerebral-to-cerebellar PIB StandardizedUptake Value ratios (SUVR) are displayed for each modality using a color coded scale.
See this image and copyright information in PMC

References

    1. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle, Jolley, Larson EB. Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol. 2002;59:1737–1746. - PubMed
    1. Brookmeyer R, Johnson E, Ziegler-Graha K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dementia. 2007;3:186–191. - PubMed
    1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. State-specific projections through 2025 of Alzheimer disease prevalence. Neurology. 2004;62:1645. - PubMed
    1. Talan J. Neuroimaging tracers for AD detection not yet ready for prime time, FDA Panel advises. Neurol Today. 2008;8:7–8.
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources